Phase II targeted therapy or immunotherapy guided by genomic profiling versus platinum based chemotherapy (3C) (after receiving three cycles of platinum based chemotherapy).
This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with poor-prognosis cancer of unknown primary site (CUP; non-specific subset) who have achieved disease control after 3 cycles of first-line platinum based induction chemotherapy.
|Eligibility criteria|| |
Cancer of Unknown Primary, please enquire for further details.
|Study details|| |
The treatment will be decided individually. While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.
|Further information|| |
For more information regarding this clinical trial click here.
North Shore NSW